论文部分内容阅读
目的:探讨结缔组织生长因子(connective tissue growth factor,CTGF)在卵巢癌组织中的表达及临床意义。方法:采用免疫组化和逆转录聚合酶链反应(RT-PCR)方法检测105例卵巢癌、20例正常卵巢组织和30例良性卵巢肿瘤组织中CTGF的表达,并分析CTGF与卵巢癌临床病理参数的关系。结果:免疫组化检测观察到CTGF主要定位于细胞质内,卵巢癌、正常卵巢组织和良性卵巢肿瘤中CTGF的阳性表达率分别为53.33%(56/105)、95.00%(19/20)、93.33%(28/30),卵巢癌中CTGF阳性表达率低于正常卵巢(χ~2=12.15,P=0.00)及良性卵巢肿瘤组织(χ~2=15.88,P=0.00),正常卵巢与良性卵巢肿瘤组织相比较差异无统计学意义(χ~2=0.05,P=0.80),RT-PCR检测结果显示卵巢癌中CTGF mRNA的表达明显低于正常卵巢组织和良性卵巢肿瘤组织(F=3.39,P=0.039)。进一步采用χ~2检验统计分析得出CTGF与卵巢癌的临床分期、淋巴转移相关(P<0.05),而与年龄、病理分级、病理类型及腹水癌细胞阳性率无相关性(P>0.05)。结论:CTGF在卵巢癌中低表达,与卵巢癌的发生、发展相关。
Objective: To investigate the expression of connective tissue growth factor (CTGF) in ovarian cancer and its clinical significance. Methods: The expressions of CTGF in 105 cases of ovarian cancer, 20 cases of normal ovarian tissue and 30 cases of benign ovarian tumor were detected by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) The relationship between the parameters. Results: The positive rates of CTGF in cytoplasm, ovarian cancer, normal ovarian tissue and benign ovarian tumor were 53.33% (56/105), 95.00% (19/20) and 93.33 (28/30). The positive rate of CTGF in ovarian cancer was lower than that in normal ovary (χ ~ 2 = 12.15, P = 0.00) and benign ovarian tumor (χ ~ 2 = 15.88, P = 0.00) The results of RT-PCR showed that the expression of CTGF mRNA in ovarian cancer was significantly lower than that in normal ovarian tissue and benign ovarian tumor (F = 3.39 , P = 0.039). Statistical analysis of χ ~ 2 test showed that CTGF was correlated with clinical stage and lymphatic metastasis (P <0.05), but not with age, pathological grade and the positive rate of ascitic carcinoma cells (P> 0.05) . Conclusion: CTGF is low expressed in ovarian cancer, which is related to the occurrence and development of ovarian cancer.